David Patteson Joins Advion BioSciences as President and CEO
News Mar 06, 2006
Advion BioSciences, Inc. has announced the appointment of Mr. David Patteson as President and Chief Executive Officer to take effect April 3, 2006.
Patteson brings to Advion over twenty years of experience in managing global businesses that develop and sell products to the analytical and organic chemistry market.
He will be responsible for overseeing the business leadership, growth and strategic development of both the Advion BioServices and Advion BioSystems business units.
Dr. Jack Henion, co-founder, and the current President, CEO and Chairman of Advion BioSciences will become Chief Scientific Officer and remain Chairman of the Board of Directors. Mr. Thomas Kurz will continue to serve as President of Advion BioServices.
"Dave Patteson possesses the integrity, business experience and leadership skills to take Advion to new heights of success as its President and CEO," said Henion.
"I am very excited about working with Dave as we continue growing Advion's core business units while also seeking new opportunities for growth."
"With Dave on board, I will now focus on important scientific and business development opportunities for both of the Advion subsidiaries."
Patteson comes to Advion after spending nearly eight years with Biotage, where he most recently held the position of President and COO, Biotage, LLC, President of the Discovery Chemistry Group and was a member of the Executive Committee of the corporate parent Biotage AB.
From 1998 to 2006, he grew the Biotage life science business significantly, acquired and integrated a number of companies, and moved the group to profitability.
From 1994-1998, Patteson managed and grew the diverse Process Analytical and Field Measurement Controls business of The Foxboro Company.
Mr. Patteson commented, "I am enthusiastic about joining Advion Biosciences as their new CEO. The company has an ideal mix of talented people and compelling technology that produces high-value products and services."
"The shareholder base is extraordinarily committed to the company's success and growth. And I relish the chance to work with an industry legend such as Jack Henion."
"I believe that with the right focus, we can take the company to the next stage of global development."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
2019 Environmental Science and Climate Change Conference
Sep 10 - Sep 11, 2019